Autologous vs. Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Follicular Non-Hodgkins Lymphoma (FL) Beyond First Complete Response or First Partial Response. In American Society of Clinical Oncology Annual Meeting. presented at the 30/05/2008, Chicago, IL. Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=55. (2008).
Informed Consent: Improving the Form and the Process. In PRIM&R: Public Responsibility in Medicine and Research. presented at the 01/12/2011, National Harbor, MD. Retrieved from http://www.primr.org/Conferences.aspx?id=11065. (2011).
Easy-to-Read Informed Consent Forms for Hematopoietic Cell Transplant Clinical Trials. Biol Blood Marrow Transplant, 18, 183-189. presented at the 02/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21806948. (2012).
Fludarabine-Based Conditioning for Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose De-Escalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. Biol Blood Marrow Transplant, 18, 1007-1011. presented at the 07/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22546497. (2012).
Tacrolimus/Sirolimus vs. Tacrolimus/Methotrexate for GVHD Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of BMT CTN Trial 0402. In 54th Annual ASH Meeting. presented at the 08/12/2012, Atlanta, GA. Retrieved from http://www.hematology.org/Meetings/Annual-Meeting/. (2012).
Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant, 20, 1530-1536. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24910380. (2014).
Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care In Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome*. Biol Blood Marrow Transplant, 20, 1566-1572. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24972249. (2014).
Phase 3 Clinical trial of Steroids/Mycophenolate Mofetil vs Steroids/Placebo as Therapy for Acute GVHD: BMT CTN 0802. Blood, 124, 3221-3227. presented at the 11/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25170121. (2014).
Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation: BMT CTN Protocol. Biol Blood Marrow Transplant, 20, 858-864. presented at the 06/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24607553. (2014).
Recommendations for Donor Human Leukocyte Antigen Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. presented at the 09/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25278457. (2014).
Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate as GVHD Prophylaxis After Matched, Related Donor Allogeneic HCT. Blood, 124, 1372-1377. presented at the 08/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24982504. (2014).